These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25577755)

  • 1. Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis.
    Chen A; Hou W; Zhang Y; Chen Y; He B
    Int J Cardiol; 2015 Mar; 182():168-70. PubMed ID: 25577755
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic value of galectin-3 in patients with heart failure.
    Bošnjak I; Selthofer-Relatić K; Včev A
    Dis Markers; 2015; 2015():690205. PubMed ID: 25960597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galectin-3, a prognostic marker--and a therapeutic target?
    Pereira AR; Menezes Falcão L
    Rev Port Cardiol; 2015 Mar; 34(3):201-8. PubMed ID: 25746675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive review of the prognostic value of galectin-3 in heart failure.
    Coburn E; Frishman W
    Cardiol Rev; 2014; 22(4):171-5. PubMed ID: 24407048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of fibroblast growth factor 23, soluble ST2 and Galectin-3 for prognostication of cardiovascular death in heart failure patients.
    Gruson D; Ferracin B; Ahn SA; Rousseau MF
    Int J Cardiol; 2015 Jun; 189():185-7. PubMed ID: 25897901
    [No Abstract]   [Full Text] [Related]  

  • 6. The predictive value of plasma biomarkers in discharged heart failure patients: role of galectin-3.
    Leone M; Iacoviello M
    Minerva Cardioangiol; 2016 Apr; 64(2):181-94. PubMed ID: 26426300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.
    Anand IS; Rector TS; Kuskowski M; Adourian A; Muntendam P; Cohn JN
    Eur J Heart Fail; 2013 May; 15(5):511-8. PubMed ID: 23291728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galectin-3 in Heart Failure: An Update of the Last 3 Years.
    Gehlken C; Suthahar N; Meijers WC; de Boer RA
    Heart Fail Clin; 2018 Jan; 14(1):75-92. PubMed ID: 29153203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of plasma galectin-3 levels in patients with coronary heart disease and chronic heart failure.
    Yu X; Sun Y; Zhao Y; Zhang W; Yang Z; Gao Y; Cai H; Li Y; Wang Q; Bian B; Nie J
    Int Heart J; 2015 May; 56(3):314-8. PubMed ID: 25902879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term Serial Measurement of Galectin-3 in Hospitalized Patients With Acute Heart Failure.
    Sánchez-Serna J; Pérez-Martínez MT; Asensio-López MC; Casas T; Noguera JA; Pascual-Figal DA
    Rev Esp Cardiol (Engl Ed); 2018 May; 71(5):401-402. PubMed ID: 28473265
    [No Abstract]   [Full Text] [Related]  

  • 11. Renal function largely influences Galectin-3 prognostic value in heart failure.
    Zamora E; Lupón J; de Antonio M; Galán A; Domingo M; Urrutia A; Troya M; Bayes-Genis A
    Int J Cardiol; 2014 Nov; 177(1):171-7. PubMed ID: 25499371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galectin-3 in heart failure: high levels are associated with all-cause mortality.
    Ueland T; Aukrust P; Broch K; Aakhus S; Skårdal R; Muntendam P; Gullestad L
    Int J Cardiol; 2011 Aug; 150(3):361-4. PubMed ID: 21641051
    [No Abstract]   [Full Text] [Related]  

  • 13. Plasma galectin-3 and heart failure outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy).
    Stolen CM; Adourian A; Meyer TE; Stein KM; Solomon SD
    J Card Fail; 2014 Nov; 20(11):793-9. PubMed ID: 25106783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. April 2015 at a glance.
    Metra M
    Eur J Heart Fail; 2015 Apr; 17(4):347. PubMed ID: 25828904
    [No Abstract]   [Full Text] [Related]  

  • 15. [Immunoanalytical characteristics of galectin-3].
    Desbène C; Gaillard O
    Ann Biol Clin (Paris); 2014; 72(4):491-9. PubMed ID: 25119810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure.
    Christenson RH; Duh SH; Wu AH; Smith A; Abel G; deFilippi CR; Wang S; Adourian A; Adiletto C; Gardiner P
    Clin Biochem; 2010 May; 43(7-8):683-90. PubMed ID: 20153309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serial galectin-3 for the monitoring of optimally treated stable chronic heart failure: A pilot study.
    Piper SE; de Courcey J; Sherwood RA; Amin-Youssef GF; McDonagh TA
    Int J Cardiol; 2016 Mar; 207():279-81. PubMed ID: 26808993
    [No Abstract]   [Full Text] [Related]  

  • 18. [Galectin-3 levels in patients hospitalized for decompensated heart failure].
    Rossel V; Díaz-Toro F; Verdejo H; Concepción R; Sepúlveda L; Castro P; Vukasovic JL; Bernales A
    Rev Med Chil; 2017 Jun; 145(6):734-740. PubMed ID: 29171621
    [No Abstract]   [Full Text] [Related]  

  • 19. Galectin-3 in cardiac remodeling and heart failure.
    de Boer RA; Yu L; van Veldhuisen DJ
    Curr Heart Fail Rep; 2010 Mar; 7(1):1-8. PubMed ID: 20425490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients.
    Lin YH; Lin LY; Wu YW; Chien KL; Lee CM; Hsu RB; Chao CL; Wang SS; Hsein YC; Liao LC; Ho YL; Chen MF
    Clin Chim Acta; 2009 Nov; 409(1-2):96-9. PubMed ID: 19747906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.